Indrayani Biotech FY26: ₹2.16 cr profit, audit caveat

Results approved at August 17 board meeting

Indrayani Biotech Ltd said its Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The approval came at a board meeting held on August 17, 2026. The company also indicated it would publish the results in newspapers and on its website, and make them available on the BSE website.

The update matters for investors because the company had earlier flagged delays in finalising and consolidating subsidiary accounts. With audited numbers now approved, the disclosure cycle for FY26 is formally complete. At the same time, the statutory auditor’s qualified opinion keeps the focus on the quality of underlying confirmations and consolidation processes.

FY26 consolidated turnaround: profit after FY25 loss

Indrayani Biotech reported a consolidated net profit of ₹2.16 crore for FY26. This marks a turnaround from the consolidated net loss of ₹6.11 crore recorded in FY25. The company’s audited disclosures highlighted this reversal as a key change year-on-year.

The FY26 consolidated performance was reported alongside revenue and quarterly details for the year-end period. For the fourth quarter, the company reported revenue of ₹74.49 crore compared to ₹53.35 crore a year earlier. Net income for the quarter was ₹1.09 crore, compared with a net loss of ₹8.53 crore in the year-ago quarter.

Revenue details: full-year and quarterly numbers

For the full year ended March 31, 2026, the company reported revenue of ₹142.40 crore compared to ₹133.35 crore a year ago. Full-year sales were ₹137.83 crore compared with ₹130.23 crore a year ago. The company also disclosed “consolidated revenue from operations” for FY26 at ₹137.83 crore.

Separately, the company stated it posted a net profit of ₹0.12 crore in its last quarter. The update adds context for investors looking at the latest run-rate, although the audited annual numbers remain the primary reference point for FY26.

Qualified audit: what the auditor flagged

Venkatesh & Co., the statutory auditors, issued a qualified opinion on both the consolidated and standalone financial results. The qualification cited uncertainties regarding unconfirmed balances, including trade receivables and loans. The auditors also pointed to issues in how subsidiaries were compiled for consolidation, noting that subsidiary consolidation was based on Indian GAAP rather than Ind AS.

A qualified opinion does not automatically mean numbers are wrong, but it signals that auditors could not fully validate certain items or that accounting treatment raised concerns. For investors, this typically increases attention on balance confirmations, inter-company positions, and the quality of subsidiary financial reporting.

Standalone picture highlighted alongside consolidated results

Along with consolidated figures, the company’s summary highlighted standalone profitability for FY26. Indrayani Biotech’s standalone net profit was stated at ₹0.70 crore for FY26, compared with ₹1.45 crore in FY25. This divergence between standalone and consolidated trajectories is relevant because the auditor’s qualification also refers to subsidiary consolidation.

The company also reported earnings per share (EPS) from continuing operations at ₹0.48 for the full year, compared with a basic loss per share of ₹1.35 in the prior year. For the fourth quarter, basic EPS from continuing operations was ₹0.24 versus a loss per share of ₹1.88 a year ago.

Earlier delay and SEBI deadline referenced by the company

Before the audited results were approved, Indrayani Biotech had disclosed that its board meeting to consider and approve the audited financial results was deferred. It attributed the delay to the consolidation of subsidiary results and the time required to complete audit processes, while stating that accounts were still being finalised.

The company also referenced a submission deadline of May 30, 2026, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It further stated that the trading window for designated persons remained closed and would reopen only 48 hours after the audited results were declared.

Key numbers at a glance

Stock and peer context mentioned with the update

Indrayani Biotech was reported trading at ₹7.32 on Tue Aug 18 2026 10:29:01. The update also listed peers of Indrayani Biotech including ITC Hotels (-1.29%), EIH (0.24%), and Chalet Hotels (-0.77%).

The company was also referenced with a market capitalisation figure of ₹58.55 crore in the same data set. While peer comparisons can be useful, the immediate investor focus is typically on audited profitability, cash conversion, and any audit qualifications.

Company profile notes included in the disclosure pack

Indrayani Biotech was described as operating in the food sector, funding projects for cut flowers, strawberries, plantlets, and hybrid vegetable seeds. It was also described as distributing Hoechst India’s hybrid seeds and aiming to produce for them in the future.

The data set also included profit figures such as -₹7.34 crore for TTM, -₹1.56 crore for Mar 2025, and ₹6.36 crore for Mar 2024. These figures provide additional context but should be read alongside the audited FY26 turnaround and the audit qualifications.

Why the FY26 update matters for investors

The FY26 turnaround in consolidated profit to ₹2.16 crore from a ₹6.11 crore loss is a clear year-on-year change. At the same time, the auditor’s qualified opinion keeps scrutiny on receivable and loan confirmations and on how subsidiaries are accounted for in consolidation. For small-cap companies, these issues can influence how investors interpret earnings quality.

Next, investors will watch for any further clarification from the company on the items behind the qualification, and for subsequent quarterly disclosures to see whether operational performance stays consistent with the FY26 profit reversal.

Timeline of key board meetings disclosed